Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel in cats against Toxocara cati and Dipylidium caninum

Special Issue – NexGard^® Combo (esafoxolaner, eprinomectin, praziquantel): A new endectocide spot-on formulation for cats. Invited Editor: Frédéric Beugnet

Open Access

Table 3

Parasite counts and efficacy.

Parasite	Study/treatment groups	Number of positive cats/number of cats in group	Geometric mean parasite count (range)	Efficacy¹ (%)	p-value²
Adult Toxocara cati	Study 1, induced infection (Tennessee, USA)
	Placebo (control)³	10/10	29.5 (14–57)	100	<0.0001
	Treated⁴	0/10	0	100	<0.0001
	Study 2, natural infection (Albania)
	Placebo (control)	10/10	12.1 (2–32)	98.8	<0.0001
	Treated	1/10	0.1 (0–3)	98.8	<0.0001
Dipylidium caninum	Study 3, induced infection (South Africa)
	Placebo (control)	7/8	28.9 (8–267)	98.0	0.0018
	Treated	2/8	0.6 (3–9)	98.0	0.0018
	Study 4, natural infection (Albania)
	Placebo (control)	9/10	23.1 (3–143)	98.3	0.0001
	Treated	2/10	0.4 (1–12)	98.3	0.0001
	Study 5, natural infection (Mexico)
	Placebo (control)	7/10	5.6 (1–370)	93.2	0.0052
	Treated	1/10	0.4 (24)	93.2	0.0052

Percent efficacy = 100[(C − T)/C], where C was the geometric mean among placebo controls and T was the geometric mean among the treated animals.

Two-sided probability value from analysis of variance on log-counts of the treated group and the placebo control group.

Mineral oil at 0.12 mL per kg bodyweight spot-on, once.

⁴

NexGard^® Combo at 0.12 mL per kg bodyweight spot-on, once.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.